Which of the following statements is true regarding Rivastigmine?

Rivastigmine is indeed delivered as a transdermal patch, which is a significant feature of its administration. This method allows for a steady release of the medication into the bloodstream over time, providing consistent therapeutic effects while reducing the risk of gastrointestinal side effects that can occur with oral forms. The transdermal patch is advantageous for patients who may have difficulties swallowing pills or for those who experience severe side effects from oral administration.

While Rivastigmine is also available in oral form, the option highlighting its alternative delivery method as a patch emphasizes the versatility of administration modalities, which can enhance patient compliance and comfort. The transdermal route is particularly beneficial since it bypasses first-pass metabolism, leading to potentially improved efficacy and decreased side effects.

Rivastigmine is indeed used in the treatment of Alzheimer's disease, making the statement about its non-use in this context incorrect. Furthermore, while allergic reactions can occur with many medications, severe allergic reactions are not a common or well-documented issue specifically associated with Rivastigmine. This makes the statement about causing severe allergic reactions misleading and less relevant in the context of its common side effects and usage profile.